Search

Your search keyword '"Michel, Gérard"' showing total 7 results
Start Over Author "Michel, Gérard" Journal bone marrow transplantation
7 results on '"Michel, Gérard"'

1. Recent results of hematopoietic stem cell transplantation for thalassemia with busulfan-based conditioning regimen in France: improved thalassemia free survival despite frequent mixed chimerism. A retrospective study from the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC)

Author

Rossi, Marica, primary, Szepetowski, Sarah, additional, Yakouben, Karima, additional, Paillard, Catherine, additional, Sirvent, Anne, additional, Castelle, Martin, additional, Pegon, Charline, additional, Piguet, Christophe, additional, Grain, Audrey, additional, Angoso, Marie, additional, Robin, Marie, additional, Dhedin, Nathalie, additional, Pondarré, Corinne, additional, Dumesnil de Maricourt, Cécile, additional, Berceanu, Ana, additional, Simon, Pauline, additional, Marcais, Ambroise, additional, Poirée, Maryline, additional, Gandemer, Virginie, additional, Plantaz, Dominique, additional, Nguyen, Stéphanie, additional, Michel, Gérard, additional, Loundou, Anderson, additional, Dalle, Jean-Hugues, additional, and Thuret, Isabelle, additional

Published
2023
Full Text
View/download PDF

2. Adenovirus infections after allogeneic hematopoietic cell transplantation in children and adults: a study from the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation

Author

Styczynski, Jan, Tridello, Gloria, Knelange, Nina, Wendel, Lotus, Ljungman, Per, Mikulska, Malgorzata, Gil, Lidia, Cesaro, Simone, Averbuch, Diana, von dem Borne, Peter, Xhaard, Aliénor, Mielke, Stephan, Neven, Benedicte, Snowden, John A., Dalle, Jean-Hugues, Rubio, Marie Thérèse, Crawley, Charles, Maertens, Johan, Kuball, Jurgen, Chevallier, Patrice, Michel, Gérard, Gabriel, Melissa, Burns, David, Wynn, Robert F., Renard, Cecile, Blijlevens, Nicole, Jubert, Charlotte, Gedde-Dahl, Tobias, Collin, Matthew, Labussiere-Wallet, Helene, Kalwak, Krzysztof, Broers, Annoek E. C., Yakoub-Agha, Ibrahim, Itäla-Remes, Maija, and de la Camara, Rafael

Abstract

The objective of the study was the analysis of clinical types, outcomes, and risk factors associated with the outcome of adenovirus (ADV) infection, in children and adults after allo-HCT. A total number of 2529 patients (43.9% children; 56.1% adults) transplanted between 2000 and 2022 reported to the EBMT database with diagnosis of ADV infection were analyzed. ADV infection manifested mainly as viremia (62.6%) or gastrointestinal infection (17.9%). The risk of 1-year mortality was higher in adults (p= 0.0001), and in patients with ADV infection developing before day +100 (p< 0.0001). The 100-day overall survival after diagnosis of ADV infections was 79.2% in children and 71.9% in adults (p< 0.0001). Factors contributing to increased risk of death by day +100 in multivariate analysis, in children: CMV seropositivity of donor and/or recipient (p= 0.02), and Lansky/Karnofsky score <90 (p< 0.0001), while in adults: type of ADV infection (viremia or pneumonia vs gastrointestinal infection) (p= 0.0004), second or higher HCT (p= 0.0003), and shorter time from allo-HCT to ADV infection (p= 0.003). In conclusion, we have shown that in patients infected with ADV, short-term survival is better in children than adults. Factors directly related to ADV infection (time, clinical type) contribute to mortality in adults, while pre-transplant factors (CMV serostatus, Lansky/Karnofsky score) contribute to mortality in children.

Published
2024
Full Text
View/download PDF

3. Cytogenetic abnormalities predict survival after allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a PDWP/EBMT study

Author

Sharma, Akshay, Galimard, Jacques-Emmanuel, Pryce, Angharad, Bhoopalan, Senthil Velan, Dalissier, Arnaud, Dalle, Jean-Hugues, Locatelli, Franco, Jubert, Charlotte, Mirci-Danicar, Oana, Kitra-Roussou, Vassiliki, Bertrand, Yves, Fagioli, Franca, Rialland, Fanny, Biffi, Alessandra, Wynn, Robert F., Michel, Gérard, Tambaro, Francesco Paolo, Al-Ahmari, Ali, Tbakhi, Abdelghani, Furness, Caroline L., Diaz, Miguel Angel, Sedlacek, Petr, Bodova, Ivana, Faraci, Maura, Rao, Kanchan, Kleinschmidt, Katharina, Petit, Arnaud, Gibson, Brenda, Bhatt, Neel S., Kalwak, Krzysztof, and Corbacioglu, Selim

Abstract

Poor-risk (PR) cytogenetic/molecular abnormalities generally direct pediatric patients with acute myeloid leukemia (AML) to allogeneic hematopoietic stem cell transplant (HSCT). We assessed the predictive value of cytogenetic risk classification at diagnosis with respect to post-HSCT outcomes in pediatric patients. Patients younger than 18 years at the time of their first allogeneic HSCT for AML in CR1 between 2005 and 2022 who were reported to the European Society for Blood and Marrow Transplantation registry were subgrouped into four categories. Of the 845 pediatric patients included in this study, 36% had an 11q23 abnormality, 24% had monosomy 7/del7q or monosomy 5/del5q, 24% had a complex or monosomal karyotype, and 16% had other PR cytogenetic abnormalities. In a multivariable model, 11q23 (hazard ratio [HR] = 0.66, P= 0.03) and other PR cytogenetic abnormalities (HR = 0.55, P= 0.02) were associated with significantly better overall survival when compared with monosomy 7/del7q or monosomy 5/del5q. Patients with other PR cytogenetic abnormalities had a lower risk of disease relapse after HSCT (HR = 0.49, P= 0.01) and, hence, better leukemia-free survival (HR = 0.55, P= 0.01). Therefore, we conclude that PR cytogenetic abnormalities at diagnosis predict overall survival after HSCT for AML in pediatric patients.

Published
2024
Full Text
View/download PDF

4. Outcome of haematopoietic cell transplantation in children with lysosomal acid lipase deficiency: a study on behalf of the EBMT Inborn Errors Working Party

Author

Lum, Su Han, primary, Minkov, Milen, additional, Jones, Simon A., additional, Hazelaar, Sheree, additional, Sirait, Tiarlan, additional, Potter, Jane E., additional, Stepensky, Polina, additional, Garban, Frederic, additional, Pichler, Herbert, additional, Stein, Jerry, additional, Kaya, Zuhre, additional, Schulz, Ansgar, additional, Mellgren, Karin, additional, Diaz de Heredia, Cristina, additional, Pochon, Cecile, additional, Riesco, Susana, additional, Diaz, Miguel Angel, additional, Michel, Gérard, additional, Lindemans, Caroline, additional, Gruhn, Bernd, additional, Albert, Michael H., additional, Lankester, Arjan C., additional, Neven, Bénédicte, additional, and Wynn, Robert, additional

Published
2023
Full Text
View/download PDF

5. Testosterone deficiency in men surviving childhood acute leukemia after treatment with hematopoietic stem cell transplantation or testicular radiation: an L.E.A. study

Author

Lopez, Romain, primary, Plat, Geneviève, additional, Bertrand, Yves, additional, Ducassou, Stéphane, additional, Saultier, Paul, additional, Berbis, Julie, additional, Pochon, Cécile, additional, Hamidou, Zeinab, additional, Poiree, Marilyne, additional, Tabone, Marie-Dominique, additional, Kanold, Justyna, additional, Dalle, Jean-Hugues, additional, Gandemer, Virginie, additional, Paillard, Catherine, additional, Sirvent, Nicolas, additional, Plantaz, Dominique, additional, Thouvenin, Sandrine, additional, Pellier, Isabelle, additional, Ansoborlo, Sophie, additional, Leverger, Guy, additional, Baruchel, André, additional, Auquier, Pascal, additional, and Michel, Gérard, additional

Published
2021
Full Text
View/download PDF

6. Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study

Author

Willasch, Andre Manfred, Peters, Christina, Sedláček, Petr, Dalle, Jean-Hugues, Kitra-Roussou, Vassiliki, Yesilipek, Akif, Wachowiak, Jacek, Lankester, Arjan, Prete, Arcangelo, Hamidieh, Amir Ali, Ifversen, Marianne, Buechner, Jochen, Kriván, Gergely, Hamladji, Rose-Marie, Diaz-de-Heredia, Cristina, Skorobogatova, Elena, Michel, Gérard, Locatelli, Franco, Bertaina, Alice, Veys, Paul, Dupont, Sophie, Or, Reuven, Güngör, Tayfun, Aleinikova, Olga, Sufliarska, Sabina, Sundin, Mikael, Rascon, Jelena, Kaare, Ain, Nemet, Damir, Fagioli, Franca, Klingebiel, Thomas Erich, Styczynski, Jan, Bierings, Marc, Nagy, Kálmán, Abecasis, Manuel, Afanasyev, Boris, Ansari, Marc, Vettenranta, Kim, Alseraihy, Amal, Chybicka, Alicja, Robinson, Stephen, Bertrand, Yves, Kupesiz, Alphan, Ghavamzadeh, Ardeshir, Campos, Antonio, Pichler, Herbert, Dalissier, Arnaud, Labopin, Myriam, Corbacioglu, Selim, Balduzzi, Adriana, Galimard, Jacques-Emmanuel, and Bader, Peter

Abstract

Although most children with acute lymphoblastic leukemia (ALL) receive fractionated total body irradiation (FTBI) as myeloablative conditioning (MAC) for allogeneic hematopoietic stem cell transplantation (allo-HSCT), it is an important matter of debate if chemotherapy can effectively replace FTBI. To compare outcomes after FTBI versus chemotherapy-based conditioning (CC), we performed a retrospective EBMT registry study. Children aged 2–18 years after MAC for first allo-HSCT of bone marrow (BM) or peripheral blood stem cells (PBSC) from matched-related (MRD) or unrelated donors (UD) in first (CR1) or second remission (CR2) between 2000 and 2012 were included. Propensity score weighting was used to control pretreatment imbalances of the observed variables. 3.054 patients were analyzed. CR1 (1.498): median follow-up (FU) after FTBI (1.285) and CC (213) was 6.8 and 6.1 years. Survivals were not significantly different. CR2 (1.556): median FU after FTBI (1.345) and CC (211) was 6.2 years. Outcomes after FTBI were superior as compared with CC with regard to overall survival (OS), leukemia-free survival (LFS), relapse incidence (RI), and nonrelapse mortality (NRM). However, we must emphasize the preliminary character of the results of this retrospective “real-world-practice” study. These findings will be prospectively assessed in the ALL SCTped 2012 FORUM trial.

Published
2020
Full Text
View/download PDF

7. Correction: Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study

Author

Willasch, Andre Manfred, Peters, Christina, Sedláček, Petr, Dalle, Jean-Hugues, Kitra-Roussou, Vassiliki, Yesilipek, Akif, Wachowiak, Jacek, Lankester, Arjan, Prete, Arcangelo, Hamidieh, Amir Ali, Ifversen, Marianne, Buechner, Jochen, Kriván, Gergely, Hamladji, Rose-Marie, Diaz-de-Heredia, Cristina, Skorobogatova, Elena, Michel, Gérard, Locatelli, Franco, Bertaina, Alice, Veys, Paul, Dupont, Sophie, Or, Reuven, Güngör, Tayfun, Aleinikova, Olga, Sufliarska, Sabina, Sundin, Mikael, Rascon, Jelena, Kaare, Ain, Nemet, Damir, Fagioli, Franca, Klingebiel, Thomas Erich, Styczynski, Jan, Bierings, Marc, Nagy, Kálmán, Abecasis, Manuel, Afanasyev, Boris, Ansari, Marc, Vettenranta, Kim, Alseraihy, Amal, Chybicka, Alicja, Robinson, Stephen, Bertrand, Yves, Kupesiz, Alphan, Ghavamzadeh, Ardeshir, Campos, Antonio, Pichler, Herbert, Dalissier, Arnaud, Labopin, Myriam, Corbacioglu, Selim, Balduzzi, Adriana, Galimard, Jacques-Emmanuel, and Bader, Peter

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results